Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 2	2026-10-06	NCT07657312
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy	Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, carcinoma, epithelial neoplasm, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, squamous cell neoplasm	Active, not recruiting	Not applicable	2026-06-03	NCT03881098
Fibulink Syndesmosis Repair System With Early Full-Weight Bearing	Ankle Fractures, Bimalleolar Equivalent Fractures, Bimalleolar Fractures, Fibula Fractures, Leg Injuries, Maisonneuve Fracture, Syndesmotic Injuries, Trimalleolar Fractures, ankle injury, bone fracture, injury	Recruiting	Not applicable	2026-03-20	NCT06085586

Clinical trials